协和麒麟发布 Crysvita（burosumab）治疗成人 XLH 的三年真实世界数据，属已上市药物的上市后证据、无新增商业或监管催化

Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (KYKOY), announced the publication of three-year real-world findings comparing burosumab with oral phosphate and active vitamin D (Pi/D) in adults with X-linked hypophosphatemia (XLH). The interim analysis of the XLH Disease Monitoring Program was published in the Journal of Bone and Mineral Research.
The analysis included 109 adults with XLH, comprising 54 treated with burosumab and 55 receiving Pi/D. Researchers assessed serum phosphate levels and patient-reported pain, stiffness and physical function at years one and three.
XLH is a rare, lifelong genetic disorder caused by excessive phosphate loss, which can weaken bones and muscles and lead to skeletal abnormalities. Burosumab is a monoclonal antibody that targets fibroblast growth factor 23 (FGF23), a key driver of phosphate loss in people with XLH.
The study provides real-world information on treatment outcomes over time. Kyowa Kirin noted that no randomized studies have directly compared burosumab with oral phosphate and active vitamin D in adults with XLH.
The XLH Disease Monitoring Program is a prospective, 10-year observational study involving adults and children in the United States, Canada and Latin America. It is designed to track disease progression and changes in biochemical measures, clinical outcomes and patient- and caregiver-reported experiences.
CRYSVITA (burosumab-twza) is approved in the United States to treat XLH in adults and pediatric patients aged six months and older. Kyowa Kirin is also generating real-world evidence through the International XLH Registry in Europe and the SUNFLOWER study in Japan and South Korea.
Currently, KYKOY is trading at $15.80, up 12.86%
For comments and feedback contact: editorial@rttnews.com
Business News
October 09, 2026 15:35 ET The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the private sector also gained attention. In Europe, results of the purchasing managers’ survey were in focus, while the Reserve Bank of India policy announcement took the center stage in Asia.